Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors
详细信息 查看全文
- 作者：Lucio Boglione ; Simone Mornese Pinna ; Chiara Simona Cardellino…
- 关键词：HCV ; Daclatasvir ; Ribavirin ; Cirrhotic ; Protease inhibitors
- 刊名：Infection
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：45
- 期：1
- 页码：103-106
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Infectious Diseases; General Practice / Family Medicine; Internal Medicine;
- 出版者：Springer Berlin Heidelberg
- ISSN：1439-0973
- 卷排序：45
文摘
BackgroundTreatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.